Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood vessel drug eluting stent

A vascular stent and drug technology, which is applied in the field of medical devices to avoid inflammation and thrombosis, reduce the risk of stent thrombosis, and reduce the rate of restenosis.

Inactive Publication Date: 2009-02-11
王显
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Stent thrombosis is a challenge faced by both DES and BMS. DES may have more thrombotic factors than BMS. Although the incidence rate is lower, the result is catastrophic, with a mortality rate of nearly 50%. PCI (coronary artery One of the leading causes of death in treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood vessel drug eluting stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The vascular drug stent of the present invention includes a vascular stent and a drug carried on the stent, and the drug is a compound of paclitaxel and its derivatives, hirudin and its recombinant product.

[0015] In the present invention, a microporous drug-loaded compartment is formed on the surface of the vascular stent by chemical corrosion, and the medicine is accommodated in the microporous drug-loaded compartment. In this way, the coating material is not used to carry the drug, which avoids the inflammatory and thrombogenic properties of the coating material itself, and also avoids the mutual adverse reaction between the coating material and the drug.

[0016] The pharmacological effects of paclitaxel and hirudin in the medicine of the present invention will be described in detail below.

[0017] Hirudin in the present invention is a direct thrombin inhibitor, and the inhibition and inactivation of thrombin are not dependent on antithrombin III, heparin cofacto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a vascular drug stent, which comprises a vascular stent and drug borne by the stent. The drug refers to a compound of paclitaxel and derivatives thereof, hirudin and recombinant products thereof. By adopting the compound consisting of paclitaxel and derivatives thereof that can effectively reduce restenosis as well as hirudin and recombinant products thereof that can most effectively and directly restrain the thrombin, the vascular drug stent eliminates coating materials and applies the drug loading technique by micropores, to realize stable release of the drug by overcoming the surface tension, thus avoiding the inflammation and thrombosis caused by the coating materials, and at the same time getting rid of untoward effect between the coating materials and the drugs. The vascular drug stent with the compound of paclitaxel and derivatives thereof, hirudin and recombinant products thereof can further reduce restenosis rates of drug-eluting stents as well as risks of stent thrombosis.

Description

technical field [0001] The invention relates to a medical device, in particular to a blood vessel drug stent. Background technique [0002] Currently, the most widely used drug-eluting stents are rapamycin and paclitaxel stents. Rapamycin is a macrolide antibiotic that can prevent cells from transitioning from G1 phase to S phase during mitosis and inhibit cell proliferation. RAVEL, SIRIUS and SinoSIRIU multicenter, prospective, randomized and double-blind trials have all confirmed that rapamycin-coated stents have a significant effect in preventing restenosis. Paclitaxel is a microtubule inhibitor, which acts on the microtubules of cells and inhibits cell replication in G1 / GO and G1 / M phases to inhibit the proliferation of cells and neointimal membranes. ELUTES, TAXUSI and other multi-center, prospective, randomized and double-blind trials have confirmed that paclitaxel stents can significantly reduce the incidence of in-stent restenosis, and have definite clinical effica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/82A61L27/28
Inventor 王显
Owner 王显
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com